Teva Announces Launch of an Authorized Generic of Epiduo® Forte Gel (adapalene and benzoyl peroxide gel 0.3%/2.5%), in the U.S.Business Wire • 12/01/21
Teva Announces Early Tender Results of its Debt Tender Offer, Increase of the Maximum Tender Amount and Election of Early SettlementBusiness Wire • 11/10/21
Teva Becomes First Pharmaceutical Company to Execute Sustainability-linked Bond Tied to both Climate and Access to Medicine TargetsBusiness Wire • 11/03/21
Teva Pharmaceuticals plans $5 billion sustainability-linked bond tied to climate and access to medicine targetsMarket Watch • 11/03/21
Teva Announces Successful Upsize of Sustainability-Linked Senior Notes Offering and Pricing of $5,000,000,000 of Sustainability-Linked Senior NotesBusiness Wire • 11/02/21
The Wall Street Journal: Opioid makers cleared of liability in California lawsuitMarket Watch • 11/02/21
California Judge Rules That Teva Did Not Cause a Public Nuisance or Make False or Misleading Statements About OpioidsBusiness Wire • 11/02/21
Teva Pharmaceutical Industries Limited (TEVA) CEO Kare Schultz on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 10/27/21
Teva Announces Launch of $4,000,000,000 Offering of Sustainability-linked Senior NotesBusiness Wire • 10/27/21
Teva and MODAG Announce Licensing Collaboration for Neurodegenerative Disease Drug CandidateBusiness Wire • 10/26/21
Teva to Present New Data from Growing Mental Health Portfolio at Psych Congress 2021Business Wire • 10/21/21